CAHAG regimen

CAHAG is an experimental combination chemotherapy regimen being investigated for the treatment of relapsed or refractory acute myeloid leukemia (AML). Developed by The First Affiliated Hospital of Soochow University, the regimen utilizes a "double epigenetic priming" strategy by combining two epigenetic modifiers—chidamide (a histone deacetylase inhibitor) and azacitidine (a hypomethylating agent)—with a chemotherapy backbone known as the HAG regimen. The HAG component in this specific protocol consists of homoharringtonine, low-dose cytarabine, and granulocyte colony-stimulating factor (G-CSF). G-CSF is used to prime dormant leukemia cells, inducing them into the cell cycle to increase their sensitivity to the cytotoxic effects of cytarabine and homoharringtonine. This multi-drug approach aims to overcome chemoresistance by modulating the epigenetic landscape and enhancing the pro-apoptotic signals in malignant cells. Chidamide is provided for these clinical trials by Shenzhen Chipscreen Biosciences.

Other names

Chidamide + Azacitidine + HAG regimenChidamide + Azacitidine + Homoharringtonine + Cytarabine + G-CSF